Methods and compositions for inhibiting enveloped viruses using high molecular weight hydrophobically modified alkali swellable emulsion polymers and surfactant
View Patent ↗This invention relates to methods and compositions for inhibiting the transmission of enveloped viruses, which entails applying a composition containing a high molecular weight hydrophobically-modified polymer to an infectable or ingestible surface that may contain viruses and wherein said anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12.
1. A method of inhibiting entry of enveloped viruses into cells comprising contacting said viruses with an anti-viral composition comprising at least one hydrophobically modified polymer having a number average molecular weight (M n ) of more than 100,000 as measured by gel permeation chromatography (GPC) calibrated with a poly(methyl methacrylate) (PMMA) standard,
wherein the hydrophobically modified polymer is a hydrophobically modified alkali swellable emulsion polymer, which is polyacrylate-33,
wherein the amount of said hydrophobically modified polymer is from about 0.00005% to about 3% by weight of the anti-viral composition,
wherein the anti-viral composition comprises less than about 9% by weight of surfactant having an HLB greater than about 12,
wherein said contacting is done by applying the anti-viral composition to skin or mucosal tissue of a subject,
wherein the formulated anti-viral composition, upon application that contacts the enveloped viruses, inhibits entry of the enveloped viruses into cells, and
wherein the enveloped virus is human immunodeficiency virus type 1 (HIV-1).
2. The method of claim 1 , wherein the anti-viral composition comprises from about 0.375% to less than about 9% by weight of surfactant.
3. The method of claim 2 , wherein the anti-viral composition comprises between about 0.375% and 6% by weight of surfactant.
4. The method of claim 2 , wherein the anti-viral composition comprises between about 0.375% and 3% by weight of surfactant.
5. The method of claim 1 , wherein the trans-epithelial permeability (TEP) of the anti-viral composition is greater than about 3.7.
6. The method of claim 1 , wherein the mucosal tissue comprises tissue selected from the group consisting of oral tissue, ocular tissue, nasal tissue, vaginal tissue, rectal tissue and a combination thereof.
7. The method of claim 1 , wherein the anti-viral composition further comprises at least 55% of water.
8. The method of claim 7 , wherein the anti-viral composition comprises at least 97% of water.
9. The method of claim 1 , wherein the inhibition of virus entry into said cells results in the reduction of potential for viral infection.
10. The method of claim 1 , wherein the anti-viral composition does not substantially disrupt biological surfaces.
11. The method of claim 1 , wherein the anti-viral composition comprises a dosage form selected from the group consisting of: a liquid, a lotion, a cream, a gel, a stick, a spray, a shaving cream, an ointment, a cleansing liquid wash, a solid bar, a shampoo, a paste, a powder, a mousse, a wipe, a patch, a wound dressing, an adhesive bandage, a hydrogel and a film.
12. The method of claim 1 , wherein the anti-viral composition further comprises nonoxynol-9.